Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Lanreotide acetate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Lanreotide acetate

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Lanreotide Solution for Injection contains the active substance lanreotide, which belongs to a group of medicines called "Antigrowth hormones". It is similar to another substance (a hormone) called "somatostatin". Lanreotide lowers the levels of hormones in the body such as growth hormone (GH), and insulin-like growth factor 1 (IGF-1) and inhibits the release of some hormones in the gastrointestinal tract and intestinal secretions. Additionally, it has an effect on some advanced type of tumours (called neuroendocrine tumours) of the intestine and pancreas by stopping or delaying their growth. What Lanreotide Solution for Injection is used for:

  • The treatment of acromegaly (a condition where your body produces too much growth hormone)
  • The relief of symptoms such as flushing and diarrhoea that sometimes occur in patients with neuroendocrine tumours (NETs)
  • The treatment and control of the growth of some advanced tumours of the intestine and pancreas called gastroenteropancreatic neuroendocrine tumours or GEP-NETs. It is used when these tumours cannot be removed by surgery. 2.

What you need to know before you take it

e Lanreotide Solution for Injection

Do not use Lanreotide Solution for Injection:

  • if you are allergicto lanreotide, somatostatin or drugs from the same family (analogues of somatostatin) or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Lanreotide Solution for Injection:

–

If you are diabetic, as Lanreotide Solution for Injection may affect your blood sugar levels. Your doctor may check your blood sugar levels and possibly alter your anti-diabetic treatment while you are receiving Lanreotide Solution for Injection If you have gallstones, as Lanreotide Solution for Injection may lead to gallstone formation in the gallbladder. In this case, you may need to be monitored periodically. Your doctor may decide to stop treatment with lanreotide if complications arising from gallstones occur If you have any thyroid problems, as Lanreotide Solution for Injection may slightly decrease your thyroid function If you have cardiac disorders, as sinus bradycardia (slower heart beat) may occur under Lanreotide Solution for Injection treatment. Special care should be taken when initiating treatment with Lanreotide Solution for Injection in patients with bradycardia.

If any of the above applies to you, talk to your doctor or pharmacist before using Lanreotide Solution for Injection. Children and adolescents Lanreotide Solution for Injection is not recommended in children and adolescents. Other medicines and Lanreotide Solution for Injection Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Special care should be taken in case of co-administration with:

  • Ciclosporin (a drug reducing immune reactions e.g. after transplantation or in cases of autoimmune disease)
  • Bromocriptine (dopamine agonist used in the treatment of certain types of tumours of the brain and Parkinson's disease, or to prevent lactation following childbirth)
  • Bradycardia inducing drugs (drugs slowing the heart beat, e.g beta blockers). Dose adjustments of such concomitant medications may be considered by your doctor. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If so, Lanreotide Solution for Injection should be given to you only if clearly needed. Driving and using machines Lanreotide solution for injection has minor or moderate influence on the ability to drive or use machines, however possible side effects such as dizziness may occur with Lanreotide Solution for Injection. If you are affected be careful when driving or using machinery. 3.

How to take it

Lanreotide Solution for Injection

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Recommended dose Treatment of acromegaly The recommended dose is one injection every 28 days. Your doctor may adapt the dose of your injection using one of the three available strengths of Lanreotide Solution for Injection (60, 90 or 120mg). If you are well controlled on your treatment, your doctor can recommend a change in the frequency of your Lanreotide120 mg injections to one injection every 42 or 56 days. Any change in dose will depend on your symptoms and how you respond to the medicine.

Your doctor will also decide how long you should be treated for. Relief of symptoms (such as flushing and diarrhoea) associated with neuroendocrine tumours The recommended dose is one injection every 28 days. Your doctor may adapt the dose of your injection using one of the three available strengths of Lanreotide Solution for Injection (60, 90 or 120 mg). If you are well-controlled on your treatment, your doctor can recommend a change in the frequency of your Lanreotide120 mg injections to one injection every 42 or 56 days. Your doctor will also decide how long you should be treated for. Treatment of advanced tumours of the intestine and pancreas called gastroenteropancreatic neuroendocrine tumours or GEP-NETs. Used when these tumours cannot be removed by surgery. The recommended dose is 120 mg every 28 days. Your doctor will decide how long you should be treated with Lanreotide Solution for Injection for tumour control. Method of administration Lanreotide Solution for Injection should be administered by deep subcutaneous injection. If the injection is being given by a healthcare professional (HCP) or someone else or a caregiver (family member or friend), the injection will be given in the upper, outer external quadrant of the buttock (see figures in section B6 below). If you are injecting yourself after appropriate training from an HCP, the injection should be given in the upper outer thigh. The decision regarding self-administration or administration by another trained person should be taken by your doctor. If you have any doubt on how to administer this injection at any time please contact your doctor or HCP for advice or further training. INSTRUCTION FOR USE Attention: Please read all the instructions carefully before starting the injection. The injection is a deep subcutaneous injection that requires a specific technique different to normal subcutaneous injections. Detailed and up-to-date information on the instructions for use of this medicine is available by scanning the QR code included in the PL with a smartphone/device. The same information is also available at the following URL: https://www.advanzpharma.com/lanreotideadvanzpharmapil A. What's in the box The following instructions explain how to inject Lanreotide Solution for Injection Please read all instructions carefully before starting the injection.

The content of the prefilled syringe is a semi-solid phase having a gel-like appearance, with viscous characteristics and a colour varying from white to pale yellow. The supersaturated solution can also contain micro bubbles that can clear up during injection. These differences are normal and do not interfere with the quality of the product. B. Before your start B1. Remove Lanreotide Solution for Injection from the refrigerator 30 minutes prior to injecting. This allows the lanreotide solution to reach room temperature, to minimize pain reaction to cold medication. Keep the laminated pouch sealed until just before the injection.

30 minutes B2. Before opening the pouch, check that it is intact and that the medication has not expired. The expiry date is printed on the outer carton and the pouch – Do not use if the medication has expired or if the pouch is damaged. B3. Wash hands with soap and dry hands thoroughly before starting. B4. Make sure there is a clean surface for preparation. B5. Tear open the pouch and take out the pre-filled syringe.

After opening the protective laminated pouch, the product should be administered immediately. B6. Choose injection site – the sites are shown below.

If you are injecting someone else: Inject into the upper outer area of the buttock.

If you are injecting yourself: Inject into the upper outer part of your thigh.

Alternate the injection site between the right and left side each time you have an injection of Lanreotide Solution for Injection. Avoid areas with moles, scar tissue, reddened skin, or skin that feels bumpy. Please note that the injection site cannot be changed once the needle has been inserted. B7. Make sure to clean the injection site. C. Get the syringe ready C1: Open the needle pack

  • Hold the needle pack and pull the lid off.
  • Caution: Do not touch the open end of the needle pack. This needs to stay clean.

C2: Remove the cap from the syringe

  • With one hand, hold the syringe barrel steady (not the plunger).
  • With the other hand, remove the cap by twisting it.

C3: Put the end of the syringe into open end of the needle pack

  • Hold the needle pack with one hand.
  • With the other, hold the syringe barrel steady (not the plunger) and screw the syringe in clockwise direction onto the needle until the syringe and needle are fully locked together. Ensure that the needle pack is in line with the syringe barrel while screw.
  • They are fully locked when you cannot turn it any further. Important: Tight the syringe firmly to avoid drug leakage.

C4: Remove the needle from the pack

  • Hold the syringe barrel (not the plunger).
  • Pull the needle straight out from the needle pack without

twisting or turning to make sure that the syringe is well connected to the safety needle. Caution: The needle is partially exposed from this step onwards.

  • NEVER TOUCH OR TRY TO OPEN THE GREEN NEEDLE

SHIELD

  • GREEN NEEDLE SHIELD is NOT a removable cap or cover

for the needle.

  • GREEN NEEDLE SHIELD will automatically activate during

the needle insertion.

  • GREEN NEEDLE SHIELD will automatically cover and lock

around the needle once the injection is complete.

  • GREEN NEEDLE SHIELD is a self-operating safety lock

mechanism.

D. Perform injection D1: Position the syringe

  • To check which site you should use, refer to section B.
  • Stretch the skin around the injection site flat and tight using your thumb and index finger. Do not pinch the skin
  • Hold the lower part of the syringe barrel (not the plunger) with your other hand.
  • Position the syringe at a 90-degree angle to the skin.

D2: Insert the needle

  • Without folding or pressing on the skin at the injection site,

push the needle firmly against the skin.

  • Insert the needle perpendicular to the skin (90-degree angle),

all the way into the skin. The Green needle shield will retract, and the safety mechanism will activate.

  • Continue to insert the needle until only the collar of the Green needle shield is visible.
  • Note: Maintain this position until the injection is completed. Avoid pulling the needle back/outward, as the safety functions may be triggered prematurely.
  • Do not push the plunger in this step. Hold the syringe in this position for the next step. Note: during injection, maintain pressure on the needle to avoid activation of the automatic safety system

D3: Push the top of the plunger

  • Release injection site that has been flattened by your hand.
  • Move your hand from the skin to the plunger.
  • Push the plunger slowly but steady with very firm pressure without interruption until the top touches the syringe barrel (it is easier to depress the plunger with your dominant hand).
  • The medication is thicker and harder to push than you might expect. Inject the full dose and give a final push to make sure you cannot depress it any further.
  • This should take around 20 seconds.

E. Remove and throw away syringe

E1: Remove from the skin Lift the syringe straight up and away from your body. The Green needle shield will cover the needle.

• •

E2: Apply gentle pressure

  • Apply gentle pressure to the injection site with a dry cotton

ball or sterile gauze to prevent any bleeding.

  • Do not rub or massage the injection site after administration.

E3: Throw away

  • Dispose of the used syringe and needle according to your

local laws and regulations or how your doctor has shown you.

  • The needles are not reusable.
  • Do not dispose of the syringe or needle in your general

household rubbish.

If you use more Lanreotide Solution for Injection than you should If you have injected more Lanreotide Solution for Injection than you should, please tell your doctor. If you have injected or if you are given too much Lanreotide Solution for Injection you may experience additional or more severe side effects (see section 4 "Possible Side Effects"). If you forget to use Lanreotide Solution for Injection As soon as you realise that you have missed an injection, contact your healthcare professional, who will give you advice about the timing of your next injection. Do not self-inject extra injections to make up for a forgotten injection, without discussing with your healthcare professional. If you stop using Lanreotide Solution for Injection

An interruption of more than one dose or early termination of the Lanreotide Solution for Injection treatment can affect the success of the treatment. Please talk to your doctor before you stop the treatment. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor immediately if you notice any of the following side effects:

  • Feeling more thirsty or tired than usual, and having a dry mouth. These may be signs that you have high blood sugar levels or are developing diabetes.
  • Feeling hungry, shaky, sweating more than usual or feeling confused. These may be signs of low blood sugar levels. The frequency of these side effects is common, it may affect up to 1 in 10 people. Tell your doctor immediately if you notice that:
  • Your face becomes flushed or swollen or you develop spots or a rash
  • Your chest feels tight, you become short of breath or wheezy
  • You feel faint, possibly as a result of a drop in blood pressure. These might be the result of an allergic reaction. The frequency of these side effects is not known; it cannot be estimated from the available data. Other side effects Tell your doctor or pharmacist if you notice any of the following side effects. The most commonly expected side effects are gastrointestinal disorders, gallbladder problems and injection site reactions. The side effects that could occur with Lanreotide Solution for Injection are listed according to their frequencies below. Very common: may affect more than 1 in 10 people:
  • Diarrhoea, loose stools, abdominal pain
  • Gallstones and other gallbladder problems. You may have symptoms such as severe and sudden abdominal pain, high fever, jaundice (yellowing of the skin and whites of the eyes), chills, loss of appetite, itchy skin. Common: may affect up to 1 in 10 people:
  • Weight loss
  • Lack of energy
  • Slow heart beat
  • Feeling very tired
  • Decrease in appetite
  • Feeling generally weak
  • Excess fat in the stools
  • Feeling dizzy, having a headache
  • Loss of hair or less development of body hair
  • Pain that affects muscles, ligaments, tendons and bones
  • Reactions where the injection is given such as pain, hard skin or itching
  • Abnormal liver and pancreas test results and changes in blood sugar levels
  • Nausea, vomiting, constipation, passing wind, stomach bloating or discomfort, indigestion
  • Biliary dilatation (enlargement of the bile ducts between your liver and gallbladder and the intestine). You may have symptoms such as stomach pain, nausea, jaundice and fever Uncommon: may affect up to 1 in 100 people:
  • Hot flushes

–

Difficulty sleeping A change in the colour of the stools Changes to sodium and alkaline phosphatase levels, shown in blood tests

Not known: frequency cannot be estimated from the available data:

  • Sudden, severe pain in your lower stomach. This may be a sign of an inflamed pancreas (pancreatitis).
  • Abscess at the site of injection which may feel fluid-filled when pressed (redness, pain, warmth and swelling which may be associated with fever)
  • Inflammation of the gallbladder (cholecystitis) – you may have symptoms such as severe and sudden pain in the upper right or centre abdomen, the pain may spread to the shoulder or back, tenderness of the abdomen, nausea, vomiting and high fever
  • Pain in the upper right part of your belly (abdomen), fever, chills, yellowing of the skin and eyes (jaundice), nausea, vomiting, clay-coloured stools, dark urine, tiredness – these may be signs of inflammation of the bile duct (cholangitis). Since Lanreotide Solution for Injection may alter your blood sugar levels, your doctor may want to monitor your blood sugar levels especially at the initiation of the treatment. Similarly, as gallbladder problems can occur with this type of medicine, your doctor may want to monitor your gallbladder when you start receiving Lanreotide Solution for Injection, and from time to time afterwards. Tell your doctor or pharmacist if you notice any of the side effects above. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Lanreotide Solution for Injection

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and label after [EXP]. The expiry date refers to the last day of that month. After opening the protective aluminum pouch, the product should be administered immediately. Store Lanreotide Solution for Injection in a refrigerator (2°C – 8°C) in the original package in order to protect from light. Once removed from the refrigerator, product left in its sealed pouch may be returned to the refrigerator (the number of temperature excursions must not exceed three times) for continued storage and later use, provided it has been stored for no longer than a total of 72 hours at a maximum temperature of 40 °C. Each syringe is packed individually. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Lanreotide Solution for Injection contains The active substance is lanreotide (60 mg, 90 mg or 120 mg) The other ingredients are water for injection and glacial acetic acid (for pH adjustment) What Lanreotide Solution for Injection looks like and contents of the pack Lanreotide Solution for Injection is a viscous solution for injection in a 0.5 mL semi-transparent plastic syringe accompanied with a single use needle-safe device. It is a white to pale yellow semisolid formulation. Each pre-filled syringe is packed in an aluminium pouch and in a carton box. Box of 0.5 mL syringe with one co-packaged safety needle (1.2 mm x 20 mm). Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder ADVANZ PHARMA Limited Unit 17, Northwood House, Northwood Crescent, Dublin 9, D09 V504, Ireland Manufacturer Pharmathen S.A Dervenakion 6, Pallini Attiki, 15351, Greece Pharmathen International S.A Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300, Greece ADVANZ PHARMA Limited is part of the ADVANZ PHARMA Group This leaflet was last revised in 02/2025.

Frequently asked questions about Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe

How do I take Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe?

Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe comes as injection containing 120mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe?

The active substance in Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe is lanreotide acetate.

Are there equivalent medicines to Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe?

Medicines with the same active substance, strength and form include: Somatuline Autogel 120 mg solution for injection in a prefilled syringe. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Lanreotide acetate (7 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Lanreotide ADVANZ PHARMA solution for injection is indicated for:

• The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.

• The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease (see section 5.1).

• The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.

4.2. Posology and method of administration

Posology

Acromegaly

The recommended starting dose is 60 mg to 120 mg administered every 28 days.

The dose may be varied according to the patient's response (judged by symptomatology and / or biochemical effect) or by the patient's possible experience with somatostatin analogues.

For example, in patients previously treated with lanreotide 30 mg with a dose every 14 days, the initial dose of Lanreotide ADVANZ PHARMA solution for injection should be 60 mg every 28 days, and in patients previously treated with lanreotide 30 mg with a dose every 10 days, the initial dose of Lanreotide ADVANZ PHARMA solution for injection should be 90 mg every 28 days.

The dose should be individualised according to the response of the patient (as judged by a reduction in symptoms and/or a reduction in GH and/or IGF-1 levels).

For patients in whom clinical symptoms and biochemical parameters are not adequately controlled, the dose of Lanreotide ADVANZ PHARMA solution for injection may be increased to a maximum of 120 mg at 28-day intervals.

If complete control is obtained (based on GH levels under 1 ng/ml, normalised IGF1 levels and/or disappearance of symptoms), the dose may be decreased.

Patients well controlled on a somatostatin analogue can alternatively be treated with Lanreotide ADVANZ PHARMA solution for injection 120 mg every 42-56 days (6 to 8 weeks).

Long term monitoring of symptoms, GH and IGF-1 levels should be routinely carried out in all patients.

Treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease

The recommended dose of Lanreotide ADVANZ PHARMA solution for injection is 120 mg administered every 28 days. The treatment with Lanreotide ADVANZ PHARMA solution for injection should be continued for as long as needed for tumour control.

Treatment of symptoms associated with neuroendocrine tumours

The recommended starting dose is 60 to 120 mg administered every 28 days.

The dose should be adjusted according to the degree of symptomatic relief obtained.

Renal and /or hepatic impairment

In patients with impaired renal or hepatic function, no dosage adjustment is necessary due to the wide therapeutic window of lanreotide (see section 5.2).

Elderly patients

In elderly patients, no dosage adjustment is necessary due to the wide therapeutic window of lanreotide (see section 5.2).

Paediatric population

Lanreotide ADVANZ PHARMA solution for injection is not recommended for use in children and adolescents due to lack of data on safety and efficacy.

Method of administration

Lanreotide ADVANZ PHARMA solution for injection is administered by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.

For patients who receive a stable dose of Lanreotide ADVANZ PHARMA solution for injection , and after appropriate training, the product may be administered either by the patient or by a trained person. In case of self-injection, the injection should be given in the upper outer thigh.

The decision regarding administration by the patient or a trained person should be taken by a healthcare professional.

Regardless of the injection site, the skin should not be folded and the needle should be inserted rapidly and to its full length, perpendicularly to the skin.

The injection site should alternate between the right and left side.

4.3. Contraindications

Hypersensitivity to the active substance, somatostatin or related peptides or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Therefore, patients may need to be monitored periodically. There have been postmarketing reports of gallstones resulting in complications, including cholecystitis, cholangitis, and pancreatitis, requiring cholecystectomy in patients taking lanreotide. If complications of cholelithiasis are suspected, discontinue lanreotide and treat appropriately.

Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogues, inhibits the secretion of insulin and glucagon. Hence, patients treated with lanreotide may experience hypoglycaemia or hyperglycaemia. Blood glucose levels should be monitored when lanreotide treatment is initiated, or when the dose is altered and any anti-diabetic treatment should be adjusted accordingly.

Slight decreases in thyroid function have been seen during treatment with lanreotide in patients with acromegaly, although clinical hypothyroidism is rare (<1%). Tests of thyroid function should be done where clinically indicated.

In patients without underlying cardiac problems, lanreotide may lead to a decrease of heart rate without necessarily reaching the threshold of bradycardia. In patients suffering from cardiac disorders prior to lanreotide treatment, sinus bradycardia may occur. Care should be taken when initiating treatment with lanreotide in patients with bradycardia (see section 4.5).

4.5. Interaction with other medicinal products and other forms of interaction

The pharmacological gastrointestinal effects of lanreotide may result in the reduction of the intestinal absorption of co-administered drugs including ciclosporin. Concomitant administration of ciclosporin with lanreotide may decrease the relative bioavailability of ciclosporin and therefore may necessitate the adjustment of ciclosporin dose to maintain therapeutic levels.

Interactions with highly plasma bound drugs are unlikely in view of the moderate binding of lanreotide to serum proteins.

Limited published data indicate that concomitant administration of somatostatin analogues and bromocriptine may increase the availability of bromocriptine.

Concomitant administration of bradycardia inducing drugs (e.g. beta blockers) may have an additive effect on the slight reduction of heart rate associated with lanreotide. Dose adjustments of such concomitant medicines may be necessary.

The limited published data available indicate that somatostatin analogues may decrease the metabolic clearance of compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that lanreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index (e.g. quinidine, terfenadine) should therefore be used with caution.

4.6. Fertility, pregnancy and lactation

Pregnancy

There is a limited amount of data (less than 300 pregnancies) from the use of lanreotide in pregnant women.

Studies in animals have shown reproductive toxicity but no evidence of teratogenic effects (see section 5.3) . The potential risk for humans is unknown.

As a precaution, the use of Lanreotide ADVANZ PHARMA solution for injection should be avoided during pregnancy.

Breast-feeding

It is not known whether this drug is excreted in human milk.

A risk to newborns/infants cannot be excluded. Lanreotide ADVANZ PHARMA solution for injection should not be used during breast-feeding

Fertility

Reduced fertility was observed in female rats due to the inhibition of GH secretion at doses in excess of those achieved in humans at therapeutic doses.

4.7. Effects on ability to drive and use machines

Lanreotide ADVANZ PHARMA solution for injection has minor or moderate influence on the ability to drive and use machines. No studies on the effects on the ability to drive and use machines have been performed.

However, dizziness has been reported with Lanreotide ADVANZ PHARMA solution for injection (see section 4.8). If a patient is affected, he/she should not drive or operate machinery.

4.8. Undesirable effects

Undesirable effects reported by patients suffering from acromegaly and GEP-NETs treated with lanreotide in clinical trials are listed under the corresponding body organ systems according to the following classification:

Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); not known (cannot be estimated from the available data).

The most commonly expected adverse drug reactions following treatment with lanreotide are gastrointestinal disorders (most commonly reported are diarrhoea and abdominal pain, usually mild or moderate and transient), cholelithiasis (often asymptomatic) and injection site reactions (pain, nodules and indurations).

The profile of undesirable effects is similar for all indications.

System organ class

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Post-marketing safety experience

(frequency not known)

Infections and infestations

Injection site abscess

Metabolism and nutrition disorders

Hypoglycaemia, decreased appetite**, hyperglycaemia, diabetes mellitus

Psychiatric disorders

Insomnia*

Nervous system disorders

Dizziness, headache, lethargy**

Cardiac disorders

Sinus bradycardia*

Vascular disorders

Hot flushes*

Gastrointestinal disorders

Diarrhoea, loose stools*, abdominal pain

Nausea, vomiting, constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia, steatorrhoea**

Faeces discoloured*

Pancreatitis

Hepatobiliary disorders

Cholelithiasis

Biliary dilatation*

Cholecystitis, cholangitis

Musculoskeletal and connective tissue disorders

Musculoskeletal pain**, myalgia**

Skin and subcutaneous tissue disorders

Alopecia, hypotrichosis*

General disorders and administration site conditions

Asthenia, fatigue, injection site reactions (pain, mass, induration, nodule, pruritus)

Investigations

ALAT increased*, ASAT abnormal*, ALAT abnormal*, blood bilirubin increased*, blood glucose increased*, glycosylated haemoglobin increased*, weight decreased, pancreatic enzymes decreased**

ASAT increased*, blood alkaline phosphatase increased*, blood bilirubin abnormal*, blood sodium decreased*

Immune system disorders

Allergic reactions (including angioedema, anaphylaxis, hypersensitivity)

* based on a pool of studies conducted in acromegalic patients

** based on a pool of studies conducted in patients with GEP-NETs

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

If overdose occurs, symptomatic management is indicated.

💬 Ask about this leaflet

Ask anything about Lanreotide ADVANZ PHARMA 120 mg solution for injection in pre-filled syringe. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →